---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-036985"
form_type: "8-K"
ticker: "IMNN"
cik: "0000749647"
company_name: "Imunon, Inc."
filed_at: "2026-08-11T12:01:29+00:00"
generated_at: "2026-08-11T12:05:12.117206+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# IMUNON Q2 net loss $2.8M; OVATION 2 shows 14.7-month OS benefit, Phase 3 on track

## Summary
- Q2 2026 net loss $2.8M ($0.54/share) vs $2.7M ($2.15/share) in Q2 2025; H1 loss $7.1M ($1.38/share).
- Cash and equivalents $6.9M at June 30, 2026; operating cash burn $7.0M in H1 2026 vs $5.8M prior year.
- OVATION 2 final data: median OS 45.1 vs 30.4 months (14.7-month gain) for IMNN-001+SoC vs SoC alone.
- Phase 3 OVATION 3 enrollment exceeds forecasts; DMC recommended continuation; completion expected H1 2029.
- Phase 2 MRD data: MRD-positive 44% vs 67%, ctDNA clearance 87.5% vs 62.5%, NED 100% vs 56% for IMNN-001 vs control.

## SEC filing metadata
- accession: 0001493152-26-036985
- form_type: 8-K
- ticker: IMNN
- cik: 0000749647
- company_name: Imunon, Inc.
- filed_at: 2026-08-11T12:01:29+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/749647/000149315226036985/0001493152-26-036985-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/749647/000149315226036985/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-036985
- JSON: https://secwatch.observer/filing/0001493152-26-036985.json
- Plain text: https://secwatch.observer/filing/0001493152-26-036985.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.